Jocelyn de Yao, MD
Internal Medicine · Colorado Springs, CONPI 1366670416
Payments from drug & device makers
What this record shows
This record is dominated by education: $38 of the $58 with a category attached, or 66.3%. 3 manufacturers reported payments, led by Mirati Therapeutics, Inc. at 36.4% of the total. That places this record below the midpoint for internal medicine clinicians in CO, where the typical reported total is $47.
Across 3 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirati Therapeutics, Inc.$21
- AbbVie$19
- E.r. Squibb & Sons, L.L.C.$17
Across 18 payments — averaging $1966.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$33K
- Merck$2K
- AstraZeneca$336
What the payments were for
- Food & beverage$1934%
- Education$3866%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirati Therapeutics, Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
How this compares
$58 in reported general payments places this provider in the 50th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 24 | $367,346 |
| TagrissoOsimertinib Mesylate | 21 | $352,896 |
| LynparzaOlaparib | 17 | $257,752 |
| BrukinsaZanubrutinib | 12 | $179,550 |
| XareltoRivaroxaban | 14 | $23,774 |
| Anastrozole | 149 | $3,118 |
| Exemestane | 20 | $2,406 |
| Hydroxyurea | 21 | $1,631 |
| Letrozole | 34 | $855 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $317 |
| Dexamethasone | 19 | $309 |
| Allopurinol | 11 | $207 |
| Gabapentin | 17 | $130 |
| Levothyroxine Sodium | 11 | $88 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $72 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Colorado Springs
- Luke WebbColorado Springs$287K
- Samuel PiedadColorado Springs$154K
- Munni SelagamsettyColorado Springs$55K
- Sridhar ReddyColorado Springs$21K
- Quinn HalversonColorado Springs$11K
- Pankaj NashikkarColorado Springs$10K
- Elizabeth CruzColorado Springs$9K
- Tayler SandersColorado Springs$7K
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.